JSSH(SZ:000518)2015-03-27 16:00Financial Performance - The company's operating revenue for 2014 was CNY 241,230,724.74, representing a 15.56% increase compared to CNY 208,745,143.93 in 2013[23]. - The net profit attributable to shareholders in 2014 was CNY 5,956,603.04, a significant turnaround from a loss of CNY 70,713,027.60 in 2013, marking an increase of 108.42%[23]. - The net cash flow from operating activities improved to CNY 20,089,635.26 in 2014, a 205.65% increase from a negative cash flow of CNY 19,015,164.86 in 2013[23]. - Basic earnings per share for 2014 were CNY 0.0058, compared to a loss of CNY 0.0687 per share in 2013, reflecting an increase of 108.44%[23]. - The company reported a net profit excluding non-recurring gains and losses of CNY 266,351.56 in 2014, a significant improvement from a loss of CNY 73,782,349.92 in 2013, marking a 100.36% increase[23]. - The company reported a net loss of CNY 412,541,527.08 for the year, slightly improved from a loss of CNY 418,498,130.12 in the previous year[171]. - The company reported a net profit of CNY -9,186,246.14, an improvement from a net loss of CNY -99,464,723.89 in the previous period[178]. - The total comprehensive income for the year was -36,117,752.71 CNY, compared to -120,189,270.65 CNY in the previous year, reflecting a reduction in losses[183]. Assets and Liabilities - The total assets at the end of 2014 were CNY 818,082,450.17, a slight decrease of 0.55% from CNY 822,583,877.99 at the end of 2013[23]. - The company's total assets at the end of 2014 were CNY 817.56 million, with a significant portion allocated to fixed assets and ongoing construction projects[45]. - The total liabilities increased to CNY 96,490,512.25 from CNY 91,805,939.43, reflecting a rise of approximately 7.4%[170]. - The total liabilities decreased from CNY 98,939,892.21 to CNY 75,159,115.65, a reduction of approximately 24%[175]. - The company has no short-term borrowings or long-term borrowings as of the end of 2014, indicating a debt-free status[170]. Shareholder Information - The total number of shares is 1,029,556,222, with no changes during the reporting period[107]. - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 3.89% of the shares, with 40 million shares pledged[110]. - The company does not have a controlling shareholder or actual controller, with no single shareholder holding more than 30% of the shares[113]. - The company’s shareholding structure is relatively dispersed, preventing any single shareholder from having substantial influence over company decisions[114]. - The company has a total of 19,630,000 shares repurchased, accounting for 1.9% of the total share capital[112]. Operational Highlights - In 2014, Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. achieved a main business revenue of CNY 234,674,481.90, representing a year-on-year growth of 15.11%[30]. - The main business cost for the same period was CNY 97,396,814.60, which decreased by 5.59% compared to the previous year[34]. - The company reported total operating income of CNY 241,230,724.74, with main business income accounting for 97.28% of total revenue[31]. - The gross profit margin for the pharmaceutical segment was 58.50%, an increase of 9.10% compared to the previous year[41]. - The revenue from EPO products was CNY 73.91 million, with a gross margin of 69.43%, showing a year-on-year growth of 66.89%[41]. Cash Flow and Investments - Cash flow from operating activities showed a net inflow of CNY 20,089,635.26, a turnaround from a net outflow in the previous year[39]. - The company’s cash and cash equivalents decreased by CNY 111,944,300.17, indicating a decline of 98.58% year-on-year[40]. - Investment cash inflow increased by 119.47% year-on-year due to the recovery of entrusted loans[40]. - Cash flow from investment activities resulted in a net outflow of -123,678,438.00 CNY, worsening from -61,459,300.13 CNY in the previous year, indicating increased investment expenditures[186]. Corporate Governance and Compliance - The company has established a comprehensive corporate governance structure, ensuring clear responsibilities and compliance with regulatory requirements[138]. - The company has not experienced any insider trading incidents during the reporting period, maintaining compliance with insider information regulations[140]. - The company has not engaged in any related party transactions during the reporting period[86][88]. - The company received a standard unqualified audit opinion from the auditing firm for the financial statements[162]. Future Outlook and Strategy - The company anticipates significant market growth in the pharmaceutical industry driven by increasing healthcare awareness and an aging population, with a focus on expanding into rural markets[64]. - The company plans to enhance market sales efforts, improve production quality management, and increase the development of new health products in 2015[66]. - The company plans to focus on expanding its market presence and developing new products in the upcoming fiscal year[167].